| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,650,459 | 4 | 100 |
| Tsur David | director | 0 | $0 | 4 | $1.65M | $-1.65M |
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver …
Over the last 12 months, insiders at Kamada Ltd. have bought $0 and sold $1.65M worth of Kamada Ltd. stock.
On average, over the past 5 years, insiders at Kamada Ltd. have bought $0 and sold $1.65M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-09-14 | Sale | Tsur David | director | 22,827 0.0388% | $8.18 | $186,725 | -3.73% | |
| 2026-09-09 | Sale | Tsur David | director | 175 0.0003% | $8.26 | $1,446 | -2.56% | |
| 2026-09-08 | Sale | Tsur David | director | 162,760 0.2801% | $8.26 | $1.34M | -3.50% | |
| 2026-09-07 | Sale | Tsur David | director | 14,238 0.0238% | $8.28 | $117,891 | -3.50% |
| Increased Positions | 32 | +72.73% | 484,560 | +8.11% |
| Decreased Positions | 19 | -43.18% | 1M | -17.87% |
| New Positions | 11 | New | 68,733 | New |
| Sold Out Positions | 10 | Sold Out | 843,872 | Sold Out |
| Total Postitions | 57 | +29.55% | 5M | -9.75% |